Antibody-drug conjugates: an emerging concept in cancer therapy.
暂无分享,去创建一个
R. Chari | Wayne C Widdison | Ravi V J Chari | Michael L. Miller | Michael L Miller | W. Widdison | Wayne C. Widdison
[1] E. Perez,et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] G. Adams,et al. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. , 2011, Cancer research.
[3] Philip S Low,et al. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. , 2008, Accounts of chemical research.
[4] S. Ansell,et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] L. Kuyper,et al. Site-specific Conjugation on Serine → Cysteine Variant Monoclonal Antibodies* , 2000, The Journal of Biological Chemistry.
[6] D. Thurston,et al. Synthesis of DNA-interactive pyrrolo[2,1-c][1,4]benzodiazepines (PBDs). , 1994, Chemical reviews.
[7] B. Löwenberg,et al. Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug. , 2013, Blood.
[8] S. Kuentzel,et al. CC-1065 (NSC-298223), a new antitumor antibiotic. Production, in vitro biological activity, microbiological assays and taxonomy of the producing microorganism. , 1978, The Journal of antibiotics.
[9] P. Carter,et al. Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97 , 2006, Molecular Cancer Therapeutics.
[10] D. Benjamin,et al. The Pharmacologic Basis for Antibody-Auristatin Conjugate Activity , 2009, Journal of Pharmacology and Experimental Therapeutics.
[11] A. Kraft,et al. Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[12] V. Israel,et al. Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer. , 2003, Lung cancer.
[13] R. Wallace,et al. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. , 1993, Cancer research.
[14] Stephen S. Taylor,et al. How do anti-mitotic drugs kill cancer cells? , 2009, Journal of Cell Science.
[15] T. Yokota,et al. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. , 1992, Cancer research.
[16] G. Hortobagyi,et al. Phase II study of adozelesin in untreated metastatic breast cancer , 1998, Anti-cancer drugs.
[17] Christopher P Leamon,et al. Engineering folate-drug conjugates to target cancer: from chemistry to clinic. , 2012, Bioconjugate chemistry.
[18] W. Leimgruber,et al. The structure of anthramycin. , 1965, Journal of the American Chemical Society.
[19] M. Berardini,et al. Rational design of a highly efficient irreversible DNA interstrand cross-linking agent based on the pyrrolobenzodiazepine ring system , 1992 .
[20] A. Lazar,et al. Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry. , 2005, Rapid communications in mass spectrometry : RCM.
[21] E. Scholar,et al. Role of Tyrosine Kinase Inhibitors in Cancer Therapy , 2005, Journal of Pharmacology and Experimental Therapeutics.
[22] C. Gilmore,et al. Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus. , 1972, Journal of the American Chemical Society.
[23] C. Fegan,et al. SG2285, a novel C2-aryl-substituted pyrrolobenzodiazepine dimer prodrug that cross-links DNA and exerts highly potent antitumor activity. , 2010, Cancer research.
[24] R. Lutz,et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. , 2006, Cancer research.
[25] B. Mills,et al. Differential distribution of free and bound glutathione and cyst(e)ine in human blood. , 1996, Biochemical pharmacology.
[26] C. Milstein,et al. Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.
[27] R. Begent,et al. Phase I Study of Sequence-Selective Minor Groove DNA Binding Agent SJG-136 in Patients with Advanced Solid Tumors , 2009, Clinical Cancer Research.
[28] Irwin Hollander,et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. , 2002, Bioconjugate chemistry.
[29] B. H. Petersen,et al. The human immune response to KS1/4-desacetylvinblastine (LY256787) and KS1/4-desacetylvinblastine hydrazide (LY203728) in single and multiple dose clinical studies. , 1991, Cancer research.
[30] S. Winstein,et al. ISOLATION AND BEHAVIOR OF SPIRO[2,5]OCTA-1,4-DIENE-3-ONE , 1957 .
[31] D. Kufe,et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. , 1980, Cancer research.
[32] N. Gray,et al. Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.
[33] R. Hertzberg,et al. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. , 1985, The Journal of biological chemistry.
[34] D. Goldenberg,et al. CEACAM5-Targeted Therapy of Human Colonic and Pancreatic Cancer Xenografts with Potent Labetuzumab-SN-38 Immunoconjugates , 2009, Clinical Cancer Research.
[35] Yelena Kovtun,et al. Semisynthetic maytansine analogues for the targeted treatment of cancer. , 2006, Journal of medicinal chemistry.
[36] J Verweij,et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[37] M. Bénéchie,et al. Total Synthesis of (-)-Maytansinol. , 1996, The Journal of organic chemistry.
[38] W. C. Krueger,et al. Cytotoxicity and antitumor activity of carzelesin, a prodrug cyclopropylpyrroloindole analogue. , 1992, Cancer research.
[39] C. Dumontet,et al. Microtubule-binding agents: a dynamic field of cancer therapeutics , 2010, Nature Reviews Drug Discovery.
[40] H. Rugo,et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] D. Benjamin,et al. Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate , 2010, Clinical Cancer Research.
[42] P. Uadia,et al. Tumor and tissue distribution of a methotrexate-anti-EL4 immunoglobulin conjugate in EL4 lymphoma-bearing mice. , 1984, Cancer research.
[43] J. Baselga,et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.
[44] S. Aamdal,et al. Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG) , 2000, Cancer Chemotherapy and Pharmacology.
[45] D. V. Von Hoff,et al. CC-1065 (NSC 298223), a most potent antitumor agent: kinetics of inhibition of growth, DNA synthesis, and cell survival. , 1982, Cancer research.
[46] T. Chittenden,et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. , 2006, Cancer research.
[47] D. Goldenberg,et al. Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys , 2011, Clinical Cancer Research.
[48] D. Boger,et al. An Efficient Synthesis of 1,2,9,9a-Tetrahydrocyclopropa[c]benz[e]indol-4-one CBI: An Enhanced and Simplified Analog of the CC-1065 and Duocarmycin Alkylation Subunits , 1995 .
[49] K. Nicolaou,et al. The enediyne antibiotics. , 1996, Journal of medicinal chemistry.
[50] E. Frei. Combination cancer therapy: Presidential address. , 1972, Cancer research.
[51] J. Sloan,et al. A Phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[52] M. Sanicola,et al. An antibody-cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumours. , 2011, European journal of cancer.
[53] M. Siegel,et al. Calichemicins, a novel family of antitumor antibiotics. 1. Chemistry and partial structure of calichemicin .gamma.1I , 1987 .
[54] Guoyao Wu,et al. Glutathione metabolism and its implications for health. , 2004, The Journal of nutrition.
[55] S. Briggs,et al. New antitumor monoclonal antibody-vinca conjugates LY203725 and related compounds: design, preparation, and representative in vivo activity. , 1989, Journal of medicinal chemistry.
[56] G A Howie,et al. Antimitotic activity of the potent tumor inhibitor maytansine. , 1975, Science.
[57] A. Verma,et al. The maytansinoids. Isolation, structural elucidation, and chemical interrelation of novel ansa macrolides. , 1977, The Journal of organic chemistry.
[58] Robert G. Bergman,et al. Reactive 1,4-dehydroaromatics , 1973 .
[59] M. Dorywalska,et al. Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. , 2013, Chemistry & biology.
[60] I Royston,et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. , 1997, Blood.
[61] D. Goldenberg,et al. Milatuzumab–SN-38 Conjugates for the Treatment of CD74+ Cancers , 2013, Molecular Cancer Therapeutics.
[62] John A Hadfield,et al. Tubulin and microtubules as targets for anticancer drugs. , 2003, Progress in cell cycle research.
[63] M. Isobe,et al. Stereocontrolled total synthesis of (-)-maytansinol , 1982 .
[64] Peter G Schultz,et al. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids , 2012, Proceedings of the National Academy of Sciences.
[65] G. Ellestad,et al. Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. , 1988, Science.
[66] J. Robb,et al. Monoclonal antibody KS1/4-methotrexate immunoconjugate studies in non-small cell lung carcinoma. , 1994, American journal of respiratory and critical care medicine.
[67] Damon L. Meyer,et al. Lysosomal Trafficking and Cysteine Protease Metabolism Confer Target-specific Cytotoxicity by Peptide-linked Anti-CD30-Auristatin Conjugates* , 2006, Journal of Biological Chemistry.
[68] H. Kantarjian,et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. , 2012, The Lancet Oncology.
[69] A. McPhail,et al. Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2 , 1966 .
[70] Scott E Smith,et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[71] D. Boger,et al. CC-1065 and the Duocarmycins: Synthetic Studies. , 1997, Chemical reviews.
[72] R. Dillman,et al. Monoclonal antibodies in cancer therapy: 25 years of progress. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[73] R. Chari,et al. Synthesis and biological evaluation of antibody conjugates of phosphate prodrugs of cytotoxic DNA alkylators for the targeted treatment of cancer. , 2012, Journal of medicinal chemistry.
[74] U. Schumacher,et al. High Interstitial Fluid Pressure Is Associated with Low Tumour Penetration of Diagnostic Monoclonal Antibodies Applied for Molecular Imaging Purposes , 2012, PloS one.
[75] Edward Chu,et al. A history of cancer chemotherapy. , 2008, Cancer research.
[76] J. Reddy,et al. Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate. , 2007, Cancer research.
[77] D. Boger,et al. An improved synthesis of 1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (CBI): a simplified analog of the CC-1065 alkylation subunit , 1992 .
[78] Dario Neri,et al. Site-specific traceless coupling of potent cytotoxic drugs to recombinant antibodies for pharmacodelivery. , 2012, Journal of the American Chemical Society.
[79] W. C. Krueger,et al. Stereoelectronic factors influencing the biological activity and DNA interaction of synthetic antitumor agents modeled on CC-1065. , 1988, Journal of medicinal chemistry.
[80] P. Trail,et al. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. , 1993, Science.
[81] Damon L. Meyer,et al. Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. , 2006, Cancer research.
[82] Damon L. Meyer,et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. , 2006, Bioconjugate chemistry.
[83] X. H. Chen,et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[84] J. Wolchok,et al. Antibody therapy of cancer , 2012, Nature Reviews Cancer.
[85] D. Goldenberg,et al. CD74: A New Candidate Target for the Immunotherapy of B-Cell Neoplasms , 2007, Clinical Cancer Research.
[86] Paul Polakis,et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index , 2008, Nature Biotechnology.
[87] D. Goldenberg,et al. Epratuzumab–SN-38: A New Antibody–Drug Conjugate for the Therapy of Hematologic Malignancies , 2011, Molecular Cancer Therapeutics.
[88] K. Nicolaou,et al. A total synthesis trilogy: calicheamicin γ1(I), Taxol®, and brevetoxin A. , 2012, Chemical record.
[89] Kenneth K. Chan,et al. Recent developments in the maytansinoid antitumor agents. , 2004, Chemical & pharmaceutical bulletin.
[90] R. Cerny,et al. Isolation and Structure of the Cytostatic Linear Depsipeptide Dolastatin 15 , 1989 .
[91] Ana T Menendez,et al. An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance. , 2005, Bioconjugate chemistry.
[92] P. Burke,et al. A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology. , 2013, Bioconjugate chemistry.
[93] M. Sliwkowski,et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates , 2012, Nature Biotechnology.
[94] A. Younes,et al. Brentuximab Vedotin (SGN-35) , 2011, Clinical Cancer Research.
[95] Rajeeva Singh,et al. Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism. , 2011, Bioconjugate chemistry.
[96] L. BogerD,et al. CC‐1065とデュオカルマイシン 新種の天然誘導DNAアルキル化剤のかぎの解明 , 1995 .
[97] J. Sloan,et al. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[98] I. Bernstein,et al. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. , 2002, Bioconjugate chemistry.
[99] H. Nakano,et al. Duocarmycins, new antitumor antibiotics produced by Streptomyces; producing organisms and improved production. , 1991, The Journal of antibiotics.
[100] J. Boehm,et al. Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activity , 1991 .
[101] E. Oroudjev,et al. Maytansine and Cellular Metabolites of Antibody-Maytansinoid Conjugates Strongly Suppress Microtubule Dynamics by Binding to Microtubules , 2010, Molecular Cancer Therapeutics.
[102] R. Pettit,et al. Specific Activities of Dolastatin 10 and Peptide Derivatives against Cryptococcus neoformans , 1998, Antimicrobial Agents and Chemotherapy.
[103] J. Scheuermann,et al. A traceless vascular-targeting antibody-drug conjugate for cancer therapy. , 2012, Angewandte Chemie.
[104] K. Gelmon,et al. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. , 1999, Journal of Clinical Oncology.
[105] Aditya A Wakankar,et al. Analytical methods for physicochemical characterization of antibody drug conjugates , 2011, mAbs.
[106] A. Mountain,et al. A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts. , 2005, Bioconjugate chemistry.
[107] I. Barasoain,et al. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. , 2003, Current cancer drug targets.
[108] G. Pfeifer,et al. Mapping of DNA alkylation sites induced by adozelesin and bizelesin in human cells by ligation-mediated polymerase chain reaction. , 1994, Biochemistry.
[109] I. Bernstein,et al. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. , 2013, Blood.
[110] E. K. Maloney,et al. Antibody-maytansinoid conjugates designed to bypass multidrug resistance. , 2010, Cancer Research.
[111] E. Sausville,et al. SJG-136 (NSC 694501), a Novel Rationally Designed DNA Minor Groove Interstrand Cross-Linking Agent with Potent and Broad Spectrum Antitumor Activity , 2004, Cancer Research.
[112] R. Bowsher,et al. Disposition of a murine monoclonal antibody vinca conjugate (KS1/4‐DAVLB) in patients with adenocarcinomas , 1990, Clinical pharmacology and therapeutics.
[113] S. Shah,et al. Enhancement of the selectivity and antitumor efficacy of a CC-1065 analogue through immunoconjugate formation. , 1995, Cancer research.
[114] K. Aldape,et al. A model of molecular interactions on short oligonucleotide microarrays , 2003, Nature Biotechnology.
[115] P. Carter,et al. Anti-CD30 diabody-drug conjugates with potent antitumor activity , 2008, Molecular Cancer Therapeutics.
[116] D. Goldenberg,et al. Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy. , 2008, Journal of medicinal chemistry.
[117] M. McNiven,et al. A novel endocytic mechanism of epidermal growth factor receptor sequestration and internalization. , 2006, Cancer research.
[118] A. Karr,et al. Isolation and characterization of anthramycin, a new antitumor antibiotic. , 1965, Journal of the American Chemical Society.
[119] Bin-Bing S. Zhou,et al. Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP , 2011, Cancer Chemotherapy and Pharmacology.
[120] M. Lee,et al. Calicheamicins: Discovery, Structure, Chemistry, and Interaction with DNA , 1991 .
[121] R. Larson,et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. , 2013, Blood.
[122] Kenneth B. Tomer,et al. The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10 , 1987 .
[123] E. Giné,et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[124] Takashi Tsuruo,et al. A BRIEF HISTORY OF CANCER CHEMOTHERAPY , 2002 .
[125] Surinder Kaur,et al. Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics. , 2013, Bioanalysis.
[126] Damon L. Meyer,et al. Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate , 2004, Clinical Cancer Research.
[127] R. Lutz,et al. Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. , 2011, Bioconjugate chemistry.
[128] L. Kèlland,et al. Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity. , 2001, Journal of medicinal chemistry.
[129] D. Boger,et al. CC-1065 and the duocarmycins: unraveling the keys to a new class of naturally derived DNA alkylating agents. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[130] E. Sausville,et al. SJG-136 (NSC 694501), A Novel Rationally Designed DNA Minor Groove Interstrand Cross-Linking Agent with Potent and Broad Spectrum Antitumor Activity , 2004, Cancer Research.
[131] P. Bringmann,et al. Site-specific modification of ED-B-targeting antibody using intein-fusion technology , 2011, BMC biotechnology.
[132] Rajeeva Singh,et al. Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates. , 2011, Journal of medicinal chemistry.
[133] S. Alberts,et al. Phase II Trial of KW2189 in Patients With Advanced Malignant Melanoma , 2002, American journal of clinical oncology.
[134] W. Lencer,et al. A passionate kiss, then run: exocytosis and recycling of IgG by FcRn. , 2005, Trends in cell biology.
[135] John P Leonard,et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. , 2010, The New England journal of medicine.
[136] R. Schultz,et al. A convergent approach to cryptophycin 52 analogues: synthesis and biological evaluation of a novel series of fragment a epoxides and chlorohydrins. , 2003, Journal of medicinal chemistry.
[137] B. Gunter,et al. The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates , 2012, Molecular Cancer Therapeutics.